AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05201794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802
Description: JNJ-64281802 tablets will be administered orally as per the defined regimens.
Study NCT05201794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for each dose level as tablet will be administered orally.
Study NCT05720013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice supplement
Description: The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.
Study NCT05720013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
Study NCT06319846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
Study NCT06094868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight \< 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W；. XELOX regimen: Oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with Fruquintinib combined with Sintilimab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~\* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator
Study NCT06319846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
Study NCT05035836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Given IV
Study NCT05035836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given by PO
Study NCT05035836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given by PO
Study NCT05155995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2001
Description: Take it once per period.
Study NCT05155995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.
Study NCT05155995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.
Study NCT05155995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take it once per period.
Study NCT05117099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
Study NCT06432036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiogram
Description: Undergo angiogram
Study NCT06432036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06432036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06432036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization
Description: Undergo radioembolization
Study NCT06432036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT
Study NCT06432036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study NCT06432036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given intra-arterially
Study NCT06559306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally.
Study NCT06559306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablets will be administered orally.
Study NCT06559306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: SSRI/SNRI will be administered orally.
Study NCT06559306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: SSRI/SNRI will be administered orally.
Study NCT04720157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Study NCT04720157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
Study NCT04720157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-PSMA-11
Description: Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
Study NCT04720157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARDT
Description: Administered orally on a continuous basis as per package insert and guideline
Study NCT04720157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARDT
Description: Administered orally on a continuous basis as per package insert and guideline
Study NCT04720157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: ADT are administered as per physician order
Study NCT04720157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: ADT are administered as per physician order
Study NCT04360928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graymont X ERIS Knee Splint
Description: Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.
Study NCT04360928 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard Hinge Knee Brace
Description: Standard knee brace used postoperatively after ACL reconstruction.
Study NCT05191901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
Study NCT06095102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06095102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06095102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT05856357 — intervention group
Intervention type: DRUG
Intervention: Sulfadoxine pyrimethamine
Description: Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
Study NCT05318092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE
Description: The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
Study NCT05747573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GB1211
Description: Hard tablet or capsules for oral use
Study NCT05296044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT-003
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05296044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JT-003 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT05793879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video 360
Description: Patients will undergo 12 sessions, 3 per weeks, 4 weeks
Study NCT05793879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard videos
Description: Patients will undergo 12 sessions, 3 per weeks, 4 weeks
Study NCT05475990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch
Description: 10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05475990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid
Description: 10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study NCT06519513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes.
Study NCT04055207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VVC
Description: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
Study NCT05218499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Description: Brigimadlin (BI 907828)
Study NCT05218499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: doxorubicin
Study NCT05923073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.
Study NCT05923073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered intravenously.
Study NCT06107738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
Study NCT06107738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20 Co-formulation
Description: Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)
Study NCT05372055 — intervention group
Intervention type: OTHER
Intervention: Semi-structure interviews
Description: Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
Study NCT03867487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
Study NCT03867487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will take an identical appearing oral tablet with zero active ingredient.
Study NCT06480591 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.
Study NCT05083169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered SC injection.
Study NCT05083169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.
Study NCT05083169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or intravenously.
Study NCT05083169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered SC injection.
Study NCT05083169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered SC injection.
Study NCT05936099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette & Tobacco Use Treatment Intervention
Description: The behavioral intervention includes health education on vaping health risk and outcomes, motivational interviewing, and assisted quit planning from a health educator and counseling and nicotine replacement therapy (if appropriate) provided by a physician.
Study NCT05406817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.
Study NCT05261399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
Study NCT05261399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral
Study NCT05261399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) Administrative route : IV infusion
Study NCT05261399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75 mg/m2) or Administrative route : IV infusion
Study NCT05261399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC5) Administrative route : IV infusion
Study NCT06045247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given by IV (vein)
Study NCT06045247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV (vein)
Study NCT06045247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study NCT06045247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given by IV (vein)
Study NCT06045247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given under the skin
Study NCT05298423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab/vibostolimab
Description: Administered as an intravenous (IV) infusion
Study NCT05298423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: durvalumab
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Administered as an IV infusion
Study NCT05298423 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: thoracic radiotherapy
Description: Administered as an external beam radiation
Study NCT05298423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Administered as an external beam radiation
Study NCT05275855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI048
Description: Oral Liquid
Study NCT05275855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Liquid
Study NCT04777396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semagludtide
Description: Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
Study NCT04777396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
Study NCT05075993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Nab-Paclitaxel
Description: Given by IV, Given by PO
Study NCT05075993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO
Study NCT05075993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Description: Given by IV, Given by PO
Study NCT05075993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO
Study NCT06576063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Home-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)
Study NCT06576063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene methods
Description: Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
Study NCT06576063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene methods
Description: Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
Study NCT06082063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
Study NCT04203199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real rTMS to the mPFC using H7 Coil
Description: This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
Study NCT06082063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c >53 mmol/mol or BMI>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
Study NCT06082063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR >30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.